{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:09:26Z","timestamp":1791846566126,"version":"4.3.4"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Melinta Therapeutics, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Delafloxacin is a recently approved anionic fluoroquinolone antibiotic with broad-spectrum activity against Gram-positive and Gram-negative organisms. The drug has been approved for patients with acute bacterial skin and skin structure infections including those caused by MRSA. There are limited data available against MRSA blood isolates (MRSABIs), vancomycin-intermediate strains (VISA), vancomycin-resistant strains (VRSA), daptomycin-non-susceptible strains (DNSSA) and linezolid-resistant Staphylococcus aureus (LRSA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Antimicrobial activity of delafloxacin, levofloxacin, vancomycin, daptomycin and linezolid was determined against 110 MRSABIs, 15 VRSA, 35 VISA, 40 DNSSA and 6 LRSA. Microdilution testing using CAMHB was used to determine MIC according to CLSI guidelines. FDA breakpoints were used to determine delafloxacin susceptibility, and CLSI breakpoints were used for all other antibiotics. PCR testing for molecular markers was performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Delafloxacin demonstrated activity against MRSABIs with an MIC90 of 1\u2009mg\/L and 68% susceptibility. Against the other groups the MIC90 and susceptibility were 1\u2009mg\/L and 40%, respectively, for VISA, 4\u2009mg\/L and 7% for VRSA and 1\u2009mg\/L and 38% for DNSSA. None of the LRSA isolates was susceptible to delafloxacin. Delafloxacin was active against 94% of MRSA blood isolates that were genotype SCC IVa. For MRSABIs with a levofloxacin MIC \u22658\u2009mg\/L (55\/110), suggesting multiple mutations in the QRDR, delafloxacin MIC90 was 1\u2009mg\/L with a 36.4% susceptibility rate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Delafloxacin demonstrates superior activity to levofloxacin against recent MRSA blood isolates, VISA, VRSA and DNSSA, and demonstrates good activity against blood isolates most commonly found in the community.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa209","type":"journal-article","created":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T19:09:14Z","timestamp":1588446554000},"page":"2605-2608","source":"Crossref","is-referenced-by-count":18,"title":["Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid"],"prefix":"10.1093","volume":"75","author":[{"given":"Louis D","family":"Saravolatz","sequence":"first","affiliation":[{"name":"Ascension-St. John Hospital, Grosse Pointe Woods, MI, USA"},{"name":"Wayne State University School of Medicine, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M","family":"Pawlak","sequence":"additional","affiliation":[{"name":"Ascension-St. John Hospital, Grosse Pointe Woods, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Wegner","sequence":"additional","affiliation":[{"name":"Ascension-St. John Hospital, Grosse Pointe Woods, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,15]]},"reference":[{"key":"2020082404584014600_dkaa209-B1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy165","article-title":"A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a Phase 3, multinational, double-blind, randomized study","volume":"67","author":"O\u2019Riordan","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020082404584014600_dkaa209-B2","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study","volume":"72","author":"Pullman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020082404584014600_dkaa209-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02609-16","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404584014600_dkaa209-B4","year":"2018"},{"key":"2020082404584014600_dkaa209-B5","year":"2019"},{"key":"2020082404584014600_dkaa209-B6","year":"1999"},{"key":"2020082404584014600_dkaa209-B7"},{"key":"2020082404584014600_dkaa209-B8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.mcp.2012.04.002","article-title":"Enhanced multiplex PCR assay for typing staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus","volume":"26","author":"Zhang","year":"2012","journal-title":"Mol Cell Probes"},{"key":"2020082404584014600_dkaa209-B9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/AAC.00165-06","article-title":"Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for mec, ccr, and major differences in junkyard regions","volume":"51","author":"Kondo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404584014600_dkaa209-B10","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1128\/JCM.41.11.5113-5120.2003","article-title":"Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database","volume":"41","author":"McDougal","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2020082404584014600_dkaa209-B11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0732-8893(03)00037-3","article-title":"Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs","volume":"46","author":"Horii","year":"2003","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/9\/2605\/33665058\/dkaa209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/9\/2605\/33665058\/dkaa209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T09:00:16Z","timestamp":1598259616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/9\/2605\/5857662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,15]]},"references-count":11,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,6,15]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa209","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,6,15]]}}}